Acinetobacter baumannii CIP 110467 is a mesophilic, Gram-negative, oval-shaped prokaryote of the family Moraxellaceae.
Gram-negative oval-shaped mesophilic genome sequence| @ref 20215 |
|
Last LPSN update
2025-12-16 10:02:24 |
| Domain Pseudomonadati |
| Phylum Pseudomonadota |
| Class Gammaproteobacteria |
| Order Pseudomonadales |
| Family Moraxellaceae |
| Genus Acinetobacter |
| Species Acinetobacter baumannii |
| Full scientific name Acinetobacter baumannii Bouvet and Grimont 1986 |
| @ref | Description | Assembly level | INSDC accession | BV-BRC accession | IMG accession | NCBI tax ID | Score | |
|---|---|---|---|---|---|---|---|---|
| 66792 | Acin_baum_NIPH_2061_V1 assembly for Acinetobacter baumannii NIPH 2061 | scaffold | GCA_000368225   | 1217645.3  | 2534681910  | 1217645 | 75.63 |  |
| Topic | Title | Authors | Journal | DOI | Year | |
|---|---|---|---|---|---|---|
| The Specific Capsule Depolymerase of Phage PMK34 Sensitizes Acinetobacter baumannii to Serum Killing. | Abdelkader K, Gutierrez D, Latka A, Boeckaerts D, Drulis-Kawa Z, Criel B, Gerstmans H, Safaan A, Khairalla AS, Gaber Y, Dishisha T, Briers Y. | Antibiotics (Basel) | 10.3390/antibiotics11050677 | 2022 | | |
| K2 Capsule Depolymerase Is Highly Stable, Is Refractory to Resistance, and Protects Larvae and Mice from Acinetobacter baumannii Sepsis. | Oliveira H, Mendes A, Fraga AG, Ferreira A, Pimenta AI, Mil-Homens D, Fialho AM, Pedrosa J, Azeredo J. | Appl Environ Microbiol | 10.1128/aem.00934-19 | 2019 | | |
| Phylogeny | Lytic Capsule-Specific Acinetobacter Bacteriophages Encoding Polysaccharide-Degrading Enzymes. | Evseev PV, Sukhova AS, Tkachenko NA, Skryabin YP, Popova AV. | Viruses | 10.3390/v16050771 | 2024 | |
| Metabolism | Functional Analysis and Antivirulence Properties of a New Depolymerase from a Myovirus That Infects Acinetobacter baumannii Capsule K45. | Oliveira H, Costa AR, Ferreira A, Konstantinides N, Santos SB, Boon M, Noben JP, Lavigne R, Azeredo J. | J Virol | 10.1128/jvi.01163-18 | 2019 | |
| Enzymology | Antivirulence drugs against Acinetobacter baumannii: where do they stand? | Elanany AA, Khalifa AG, Attia AS. | World J Microbiol Biotechnol | 10.1007/s11274-025-04593-3 | 2025 | |
| Development of an Anti-Acinetobacter baumannii Biofilm Phage Cocktail: Genomic Adaptation to the Host. | Blasco L, Bleriot I, Gonzalez de Aledo M, Fernandez-Garcia L, Pacios O, Oliveira H, Lopez M, Ortiz-Cartagena C, Fernandez-Cuenca F, Pascual A, Martinez-Martinez L, Pachon J, Azeredo J, Tomas M. | Antimicrob Agents Chemother | 10.1128/aac.01923-21 | 2022 | | |
| Pathogenicity | Deciphering Multifactorial Resistance Phenotypes in Acinetobacter baumannii by Genomics and Targeted Label-free Proteomics. | Cecchini T, Yoon EJ, Charretier Y, Bardet C, Beaulieu C, Lacoux X, Docquier JD, Lemoine J, Courvalin P, Grillot-Courvalin C, Charrier JP. | Mol Cell Proteomics | 10.1074/mcp.ra117.000107 | 2018 | |
| Genomic analysis of Acinetobacter baumannii prophages reveals remarkable diversity and suggests profound impact on bacterial virulence and fitness. | Costa AR, Monteiro R, Azeredo J. | Sci Rep | 10.1038/s41598-018-33800-5 | 2018 | | |
| Database for the ampC alleles in Acinetobacter baumannii. | Karah N, Jolley KA, Hall RM, Uhlin BE. | PLoS One | 10.1371/journal.pone.0176695 | 2017 | | |
| Potential of phage depolymerase for the treatment of bacterial biofilms. | Guo Z, Liu M, Zhang D. | Virulence | 10.1080/21505594.2023.2273567 | 2023 | | |
| Enzymology | Origin in Acinetobacter guillouiae and dissemination of the aminoglycoside-modifying enzyme Aph(3')-VI. | Yoon EJ, Goussard S, Touchon M, Krizova L, Cerqueira G, Murphy C, Lambert T, Grillot-Courvalin C, Nemec A, Courvalin P. | mBio | 10.1128/mbio.01972-14 | 2014 | |
| Phylogeny | Identification of 50 class D beta-lactamases and 65 Acinetobacter-derived cephalosporinases in Acinetobacter spp. | Perichon B, Goussard S, Walewski V, Krizova L, Cerqueira G, Murphy C, Feldgarden M, Wortman J, Clermont D, Nemec A, Courvalin P. | Antimicrob Agents Chemother | 10.1128/aac.01261-13 | 2014 | |
| Biological challenges of phage therapy and proposed solutions: a literature review. | Caflisch KM, Suh GA, Patel R. | Expert Rev Anti Infect Ther | 10.1080/14787210.2019.1694905 | 2019 | |
How to citeIf you want to cite this particular strain cite the following doi:
https://doi.org/10.13145/bacdive135763.20251217.10
When using BacDive for research please cite the following paper
BacDive in 2025: the core database for prokaryotic strain data
License